<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809718</url>
  </required_header>
  <id_info>
    <org_study_id>TBTC 29RR</org_study_id>
    <nct_id>NCT00809718</nct_id>
  </id_info>
  <brief_title>The Effect of Rifapentine on Raltegravir</brief_title>
  <official_title>The Effect of Rifapentine on Plasma Concentrations of Raltegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to study the effect of rifapentine on plasma concentrations of&#xD;
      raltegravir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective&#xD;
&#xD;
      To compare the pharmacokinetics parameter values (geometric mean Cmin and AUC) of raltegravir&#xD;
      at 400 mg q12h alone to raltegravir at 400 mg q12h co-administered in combination with&#xD;
      rifapentine 900 mg once weekly, and to raltegravir at 400 mg q12h co-administered in&#xD;
      combination with rifapentine 600 mg per day, 5 days per week.&#xD;
&#xD;
      Secondary Objective&#xD;
&#xD;
      To assess the tolerability and safety of concomitant administration of raltegravir and&#xD;
      rifapentine in healthy volunteers.&#xD;
&#xD;
      Design&#xD;
&#xD;
      This study is a three-period, one-sequence, open label, pharmacokinetic study of the&#xD;
      raltegravir-rifapentine interactions in healthy, male and female volunteers. Up to 21&#xD;
      subjects may be enrolled to achieve the estimated sample size of 16 completing subjects. All&#xD;
      study medication will be self-administered except on the days of pharmacokinetic sampling.&#xD;
      All subjects will participate in three sampling periods and be studied in a day clinic or be&#xD;
      admitted overnight to a hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Raltegravir pharmacokinetics (Cmin and AUC)</measure>
    <time_frame>Eight weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety of concomitant raltegravir and rifapentine administration</measure>
    <time_frame>Eight weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>raltegravir and rifapentine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concomitant administration of raltegravir and rifapentine in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir and rifapentine</intervention_name>
    <description>Period 1- Raltegravir 400 mg q12h by mouth for 4 days&#xD;
Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days&#xD;
Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days</description>
    <arm_group_label>raltegravir and rifapentine</arm_group_label>
    <other_name>Isentress - Raltegravir</other_name>
    <other_name>Priftin - Rifapentine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-nursing female age &gt; 18 years in good health&#xD;
&#xD;
          -  Provision of informed consent for the study.&#xD;
&#xD;
          -  HIV-uninfected. A prior negative HIV test (ELISA) must be obtained before enrollment.&#xD;
&#xD;
          -  Willingness to have PK sampling in a day clinic or to be admitted overnight to a&#xD;
             hospital on three occasions.&#xD;
&#xD;
          -  Women of child-bearing potential must agree to practice an adequate method of birth&#xD;
             control during the study and for 30 days after the last dose of study medication.&#xD;
             Barrier methods of contraception or abstinence from sexual activity are satisfactory&#xD;
             methods of birth control.&#xD;
&#xD;
          -  Karnofsky score â‰¥ 90.&#xD;
&#xD;
          -  Laboratory screening before enrollment:&#xD;
&#xD;
               -  Hematocrit &gt; 30 percent (most recent value)&#xD;
&#xD;
               -  AST &lt; 2 times the upper limit of normal&#xD;
&#xD;
               -  ALT &lt; 2 times the upper limit of normal&#xD;
&#xD;
               -  Bilirubin &lt; 2 times the upper limit of normal&#xD;
&#xD;
               -  Creatinine &lt; 1.5 times the upper limit of normal&#xD;
&#xD;
               -  Negative urine drug screen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Use of a medication or food that has the potential to alter the concentrations of&#xD;
             raltegravir or rifapentine, within the 14 days prior to or during the periods of&#xD;
             pharmacokinetic monitoring.&#xD;
&#xD;
          -  Known intolerance to raltegravir or rifamycin antibiotics or prior use in the last 30&#xD;
             days.&#xD;
&#xD;
          -  Weight less than 46 kg or greater than 102 kg.&#xD;
&#xD;
          -  Prior gastrointestinal surgery.&#xD;
&#xD;
          -  Infection with Hepatitis B or Hepatitis C by serologies.&#xD;
&#xD;
          -  Co-morbidity for which concomitant, current medications are taken regularly. If&#xD;
             concomitant medications are taken intermittently, these medications should not have&#xD;
             potential to alter the concentrations of raltegravir or rifapentine.&#xD;
&#xD;
          -  Current imprisonment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Weiner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L Murphy Veterans Administration Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Rifapentine</keyword>
  <keyword>Drug Kinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

